NEW YORK, NY--(Marketwire - June 30, 2010) - Corporate Profile, LLC announced today that Pluristem Therapeutics, Inc. (NASDAQ: PSTI) CEO, Zami Aberman, was interviewed on CorporateProfile.com.
Pluristem announced Monday that they are advancing toward designing two Phase IIB clinical trials for its placenta-derived cell therapy product, PLXPAD for the treatment of Critical Limb Ischemia (CLI) and Moderate-severe Claudication. They were also awarded $2.5 million this week from the Office of the Chief Scientist at the Ministry of Industry, Trade and Labor of Israel for expenses from the period March 2010 to February 2011.
The video can be viewed at: www.corporateprofile.com.
About Pluristem
Pluristem is a clinical stage biotechnology company with proprietary technology for the development and manufacturing of standardized cell therapies derived from the human placenta. Pluristem’s patented and scalable PLX (Placental expanded) cell product candidates are developed as readily available for the treatment of critical limb ischemia (CLI) and other diseases.
For more information visit the company website at http://www.pluristem.com
About Corporate Profile.com
CorporateProfile.com is a broadcasting website where Fashion meets Finance. Merging two mainstream industries results in the unique platform for investors to receive today’s hottest tips and market info.
Safe Harbor Disclaimer
Under The Private Securities Litigation Reform Act of 1995: Except for historical information contained herein, the statements in this news release are forward-looking statements that are made pursuant to the safe harbor provisions of the Private Securities Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which may cause a company’s actual results, performance and achievement in the future to differ materially from forecasted results, performance, and achievement. These risks and uncertainties are described in the Company’s periodic filings with the Securities and Exchange Commission. The Company undertakes no obligation to publicly release the results of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date hereof, or to reflect the occurrence of unanticipated events or changes in the Company’s plans or expectation.
